Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23682669 | 0.80 | GFER (0.36) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL25697722 | 0.76 | GFER (0.33) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL14534656 | 0.70 | MEN1 (0.34) | ALDH1A1LMNAGAARORC | |
| SCHEMBL23815752 | 0.67 | GAA (0.44) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL23815725 | 0.67 | SHMT2 (0.39) | CDK2CCNA2L3MBTL1ALDH1A1POLB | |
| SCHEMBL6842163 | 0.66 | KMT2A (0.48) | GFERCDK2CCNA2L3MBTL1ALDH1A1 | |
| SCHEMBL25697068 | 0.66 | ALDH1A1 (0.31) | ALDH1A1GAA | |
| SCHEMBL26546527 | 0.65 | CDK2 (0.38) | CDK2CCNA2ALDH1A1LMNAGAA | |
| SCHEMBL1841799 | 0.65 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1RORC | |
| SCHEMBL2880579 | 0.64 | COPS5 (0.35) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | GFER 2643/4885CDK2 1489/4885CCNA2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.